ArticleBMC cancer2024

Adverse events after nivolumab and ipilimumab combined immunotherapy in advanced renal cell carcinoma: a multicentre experience in Poland.

Renata Pacholczak-Madej et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.